Cidara Therapeutics, Inc. (CDTX)

NASDAQ: CDTX · IEX Real-Time Price · USD
0.695
+0.030 (4.54%)
At close: Nov 25, 2022 1:00 PM
0.694
-0.001 (-0.14%)
After-hours: Nov 25, 2022 4:12 PM EST
4.54%
Market Cap 50.07M
Revenue (ttm) 61.29M
Net Income (ttm) -36.31M
Shares Out 70.22M
EPS (ttm) -0.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 76,037
Open 0.662
Previous Close 0.665
Day's Range 0.634 - 0.7
52-Week Range 0.4 - 1.71
Beta 1.43
Analysts Buy
Price Target 5.71 (+721.6%)
Earnings Date Nov 9, 2022

About CDTX

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its... [Read more]

Industry Biotechnology
IPO Date Apr 15, 2015
CEO Jeffrey Stein
Employees 89
Stock Exchange NASDAQ
Ticker Symbol CDTX
Full Company Profile

Financial Performance

In 2021, CDTX's revenue was $49.57 million, an increase of 310.81% compared to the previous year's $12.07 million. Losses were -$42.47 million, -41.11% less than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for CDTX stock is "Buy." The 12-month stock price forecast is 5.71, which is an increase of 721.58% from the latest price.

Price Target
$5.71
(721.58% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Cidara Therapeutics to Participate in the World Antiviral Congress 2022

SAN DIEGO, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients f...

2 days ago - GlobeNewsWire

Cidara Therapeutics to Present at the Stifel Healthcare Conference

SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients f...

2 weeks ago - GlobeNewsWire

Cidara Therapeutics (CDTX) Q3 Earnings Miss Estimates

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -43.33% and 8.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patie...

3 weeks ago - GlobeNewsWire

Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2022

SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients f...

1 month ago - GlobeNewsWire

Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma

Milestone payment triggered by European Medicines Agency acceptance of marketing authorization application for rezafungin

1 month ago - GlobeNewsWire

Cidara Therapeutics Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treat...

Assigned PDUFA target action date of March 22, 2023 Assigned PDUFA target action date of March 22, 2023

2 months ago - GlobeNewsWire

Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Evaluate CD388 for Universal Prev...

CD388 is a drug-Fc conjugate (DFC) from Cidara's Cloudbreak ® platform designed to help transform the standard of care for seasonal and pandemic influenza prevention

2 months ago - GlobeNewsWire

Cidara Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference

SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients ...

2 months ago - GlobeNewsWire

Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 32.14% and 14.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients f...

3 months ago - GlobeNewsWire

Melinta Therapeutics and Cidara Therapeutics Announce Licensing Agreement to Commercialize Rezafungin in the U.S.

MORRISTOWN, N.J.--(BUSINESS WIRE)--Melinta Therapeutics, LLC (“Melinta”) and Cidara Therapeutics (“Cidara”) today announced that they have entered into a License Agreement (the “Agreement”) to facilitat...

3 months ago - Business Wire

Cidara Therapeutics Submits NDA for Rezafungin and Announces License Agreement with Melinta Therapeutics for Commerci...

SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) fo...

3 months ago - GlobeNewsWire

Cidara Therapeutics to Host Research and Development Day

Virtual panel discussion will highlight the company's Cloudbreak ® platform and its potential advantages in oncology

4 months ago - GlobeNewsWire

Tentarix Biotherapeutics Announces the Strengthening of its Leadership and Advisory Teams

SAN DIEGO & VANCOUVER, British Columbia--(BUSINESS WIRE)--Tentarix Biotherapeutics LP, a biotechnology company developing first-in-class targeted, conditional antibody-based multifunctional biotherapies...

6 months ago - Business Wire

Read Why HC Wainwright Lowered Price Target On This Small Biotech Stock

U.S. marketing application filing for Cidara Therapeutics Inc's (NASDAQ: CDTX) rezafungin remains on track for mid-2022, setting up a potential early 2023 approval and launch.  Cidara confirmed that the...

6 months ago - Benzinga

Cidara Therapeutics (CDTX) Reports Q1 Loss, Lags Revenue Estimates

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -3.85% and 3.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients fa...

6 months ago - GlobeNewsWire

Mundipharma and Cidara Therapeutics Announce First Presentation of Results from Global Phase 3 ReSTORE Trial of Rezaf...

SAN DIEGO & CAMBRIDGE, England--(BUSINESS WIRE)--Mundipharma and Cidara Therapeutics, Inc. (NASDAQ: CDTX) today presented data from the Phase 3 ReSTORE clinical trial of rezafungin in the treatment of c...

7 months ago - Business Wire

Cidara Therapeutics and Mundipharma to Present Results from Global Phase 3 ReSTORE Trial of Rezafungin for the Treatm...

SAN DIEGO and CAMBRIDGE, United Kingdom, April 14, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX) and Mundipharma today announced that the companies will present new clinical data and...

7 months ago - GlobeNewsWire

Cidara Therapeutics Announces the Completion of Dosing the First Cohort of Healthy Volunteers in the Phase 1 Trial of...

CD388 is a drug-Fc conjugate (DFC) from Cidara's Cloudbreak® platform and is designed to transform the standard of care for seasonal influenza prevention

7 months ago - GlobeNewsWire

Cidara Therapeutics (CDTX) Reports Q4 Loss, Tops Revenue Estimates

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 21.21% and 84.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients ...

8 months ago - GlobeNewsWire

Rezafungin Awarded Promising Innovation Medicine (PIM) Designation by the UK's Medicines and Healthcare Products Regu...

CAMBRIDGE, England & SAN DIEGO--(BUSINESS WIRE)--Mundipharma and Cidara Therapeutics, Inc. (NASDAQ: CDTX) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK ha...

8 months ago - Business Wire

Will Cidara Therapeutics (CDTX) Report Negative Q4 Earnings? What You Should Know

Cidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research